For people with metastatic PDL1+ TRIPLE NEG BREAST CANCER, Sacituzumab+pembrolizumab (P) significantly increases PFI by ~3m vs chemo+P (a 35% improvement). Whether its meaningful depends on the person offered it and whether it will ultimately improve OS. #ASCENT meetings.asco.org/abstracts-pr... 8/8

For people with advanced hormone receptor positive PIK3CA mutated BREAST CANCER, 1st line tx w/ inavolisib|palbociclib|fulvestrant (PF) increased OS over placebo + PF by 7 months- an almost 30% improvement. 30-month overall survival was also improved by 10%. meetings.asco.org/abstracts-pr... 7/8

Its not a randomized trial, but the results are reassuring. #KCSGBR18-2 www.asco.org/abstracts-pr... 6b/8

For people with metastatic triple-positive BREAST CANCER (Hormone and HER2 positive), one trial of 77p reported that ribociclib, trastuzumab, and letrozole resulted in a 61% overall response rate and median progression-free interval of 30 months. 6a/8

Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8

In the absence of frank disease progression, for people with hormone-positive BREAST CANCER, the only reason to switch treatment from an aromatase inhibitor (AI) to a selective estrogen receptor degrader (SERD) is if toxicity is making it hard to take the AI. 5a/8

Interestingly, the OS benefit was bigger than the Progression Free Interval which was improved by only one month. It also added no additional toxicity to treatment. 4b/8 #ROSELLA ascopubs.org/doi/10.1200/...

For people with platinum-resistant recurrent OVARIAN CANCER, a novel drug that targets the glucocorticoid receptor, called Relacorilant, in combination with nAb-paclitaxel improved overall survival (OS) by 5 months over nAb-paclitaxel alone. 4a/8 #ROSELLA

For people with OVARIAN CANCER, surgery should be done if their gyn onc feels they can have all tumor resected rather than undergoing medical therapy (neo adjuvant chemo) first. That’s been the standard everywhere I’ve worked and the #TRUST trial affirms this. meetings.asco.org/abstracts-pr... 3/8

PFS (Progression Free Survival) needs to be renamed. People don’t experience “progression”. A cancer may progress at some interval, and that’s what it should be called: PFI. The only survival is whether one is alive or dead- OS (Overall Survival). We need to stop conflating them. 2/8

Yes, so great to see you

Have fun at your #asco25 session. I will be watching remotely and rooting for you all the same.

Blush

I'm proud to be a part of this international community seeking to improve both access and outcomes for people with breast cancer worldwide.

Huge congratulations!!!!